The report “Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region — Global Forecast to 2029”, is expected to grow from USD 0.65 billion in 2024 to 0.91 billion in 2029 at a CAGR of 7.1% . The increasing prevalence of prostate cancer and the growing geriatric population, the availability of reimbursements & investments by the public and private sectors, and the increasing prevalence of minimally invasive surgery contribute to the market growth. Furthermore, technological advancements in fusion biopsy devices offer growth opportunities for market players in this market.
Browse 191 market data Tables and 45 Figures spread through 196 Pages and in-depth TOC on “Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region — Global Forecast to 2029”View detailed Table of Content here — https://www.marketsandmarkets.com/Market-Reports/fusion-biopsy-market-228439168.html
In 2023, the transrectal segment held the largest share of the fusion biopsy market, by route type segment.
Based on route type, the global fusion biopsy market is segmented into transrectal, transperineal, and other route types. In 2023, transrectal led the fusion biopsy market. Due to its extensive use in the diagnosis of prostate cancer, the transrectal approach accounts for the biggest portion of the fusion biopsy market. Because of its extensive knowledge among urologists, well-established clinical procedures, ease of access to the prostate, and quicker procedure duration, it is the recommended method for fusion biopsy.
“The prostate cancer segment is projected to witness the highest growth rate in the fusion biopsy market, in 2023, by application”
The market for fusion biopsy is divided into segments based on application, such as prostate cancer and others. Due to the rising incidence of prostate cancer worldwide and the growing need for precise diagnostic methods, the prostate cancer segment of the fusion biopsy market is projected to develop at the fastest rate. As prostate cancer remains a leading concern in men’s health, this segment will continue to drive the adoption of fusion biopsy systems worldwide.
Download PDF Brochure- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=228439168
The Europe market the highest share of fusion biopsy market in 2023.
The global fusion biopsy market is segmented into six distinct regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and GCC Countries. The Europe holds the highest share of 33.7% of global fusion biopsy market in 2023. The high share of Europe market can be attributed to the growing geriatric population, extensive healthcare expenditure and supportive government investments support the fusion biopsy market in this region. High demand for diagnosis of prostate cancer along with supportive regulatory environment in Europe for new technologies has also driven the growth of the market.
Prominent players in the market include Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China).
Recent Developments of Fusion Biopsy Market-FUJIFILM Healthcare announced, effective April 6th, 2023, the release of the new ARIETTA 65 IntuitiveFusion, an MRI-Ultrasound fusion system extending its engineering process to help further enhance efficiency during prostate biopsies. With improved precision, it will enhance prostate biopsy procedures in a seamless way.-September 2023: Koelis DeepHealth has announced a partnership that will see users of the Koelis Trinity 3D Ultrasound Platform have access to DeepHealth’s Prostate AI software for efficient interpretation of the prostate MRI and guidance of prostate fusion biopsies.
Commentaires